Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00000952 · ClinicalTrials.gov registry record · Phase 1

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

A Phase 1 study of HIV Infections, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
12
Study locations

NCT00000952 is a Phase 1 study of HIV Infections that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 60 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The trial reports 12 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00000952, a Phase 1 study of HIV Infections, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
12
Study locations

Study Summary

The study examines the safety and effectiveness of ritonavir (an anti-HIV drug), alone and in combination with other anti-HIV drugs, in HIV-positive children under 2 years of age. This study will also determine the most effective doses of ritonavir for future pediatric HIV studies. Infants infected with HIV by their mothers experience faster disease progression than adults or older children. Treatment with anti-HIV drugs administered at an early age may slow disease progression in infant populations.

Conditions Studied

HIV Infections

Interventions

  • DRUG Zidovudine
  • DRUG Lamivudine
  • DRUG Ritonavir

Study Locations (12)

New York

  • NYU Med. Ctr., Dept. of Medicine - New York
  • Nyu Ny Nichd Crs - New York
  • Columbia IMPAACT CRS - New York
  • Incarnation Children's Ctr. - New York
  • Harlem Hosp. Ctr. NY NICHD CRS - New York

California

  • Long Beach Memorial Med. Ctr., Miller Children's Hosp. - Long Beach
  • UCSD Maternal, Child, and Adolescent HIV CRS - San Diego

District of Columbia

  • Howard Univ. Washington DC NICHD CRS - Washington D.C.

Louisiana

  • Tulane/LSU Maternal/Child CRS - New Orleans

Massachusetts

  • HMS - Children's Hosp. Boston, Div. of Infectious Diseases - Boston

Pennsylvania

  • The Children's Hosp. of Philadelphia IMPAACT CRS - Philadelphia

Tennessee

  • St. Jude/UTHSC CRS - Memphis

Trial Details

FieldValue
Enrollment Target 60 participants
Est. Completion 2004-01
Phase Phase 1

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

2,006 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00000952

The ClinicalTrials.gov registry entry for NCT00000952 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (87% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.

NCT00000952 reports 12 study locations spanning 7 distinct geographic areas - top geographies include New York, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00000952 about?

NCT00000952 is a clinical study titled "A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children". The study examines the safety and effectiveness of ritonavir (an anti-HIV drug), alone and in combination with other anti-HIV drugs, in HIV-positive children under 2 years of age. This study will also determine the most effective doses of ritonavir for future pediatric HIV studies. Infants infected...

What is the current status of trial NCT00000952?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. Estimated completion is 2004-01.

What conditions does trial NCT00000952 study?

This clinical trial studies the following conditions: HIV Infections.

What interventions are being tested in trial NCT00000952?

The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Ritonavir (DRUG).

Who is sponsoring clinical trial NCT00000952?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00000952 being conducted?

This trial has 12 study locations across California, District of Columbia, Louisiana, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for HIV Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

HIV Infections

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.